SCHEMBL2557643

SCHEMBL2557643

O=S(=O)(c1ccc(F)cc1)N1CC(F)(F)C1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 6/20 0.58
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 1/20 0.51
ALDH1A1 P00352 3/20 0.50
HPGD P15428 1/20 0.50
MMP2 P08253 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 2/20 0.47
PKLR P30613 1/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15765139 0.83 MMP2 (0.49) ALDH1A1MMP2LMNATSHRHTT
SCHEMBL21510169 0.83 PKM (0.59) PKMMEN1KMT2AALDH1A1POLB
SCHEMBL18977620 0.82 CYP2C9 (0.55) PKMMEN1KMT2AALDH1A1HPGD
SCHEMBL14837469 0.81 PKM (0.64) PKMMEN1KMT2AMAPTALDH1A1
SCHEMBL2174608 0.80 TSHR (0.55) PKMMEN1KMT2AMAPTALDH1A1
SCHEMBL1711115 0.79 PKM (0.85) PKMMEN1KMT2AMAPTALDH1A1
SCHEMBL16372253 0.79 NAMPT (0.39) PKMALDH1A1POLBPKLRTSHR
SCHEMBL13324056 0.79 PKM (0.51) PKMMEN1KMT2AMAPTALDH1A1
SCHEMBL19746052 0.79 AKR1C3 (0.51) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL2442349 0.77 PKM (0.66) PKMMEN1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2556056-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2013-02-13 EP disclosed
US-20130023494-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-01-24 US disclosed
WO-2011127051-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023494-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO GPR119, SLC5A2, SLC5A1 PKM 2570/4885MEN1 4549/4885KMT2A 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.